In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prolysis Ltd.

Latest From Prolysis Ltd.

Wellcome Trust extends funding initiative for early stage drug discovery

The Wellcome Trust will continue to help fund the early stages of drug discovery for another five years by extending its Seeding Drug Discovery initiative with a further £110 million.

Biota acquires antibacterial projects from two firms

Biota Holdings has acquired early stage antibacterial programmes from the UK firm Prolysis and MaxThera of the US, in an effort to extend its research interests beyond antivirals and into the wider anti-infective area.

Infectious Diseases Respiratory

Prolysis Ltd.

Prolysis Ltd. reckons it has a head start over other biotechs seeking novel anti-infectives because its core technology--a series of whole cell assays targeting critical bacterial pathways--allows it to select, early on, only those compounds that get inside the bacterial cell.


Biotechs Battle Bacteria

The rise in bacterial resistance has prompted a plethora of creative approaches to developing antibiotics. These range from finding completely novel targets to harnessing the body's own immune system to fight bacteria. And although biotechs have had the anti-bacterials space to themselves for the last few years, as more programs reach proof of concept, some Big Pharma may be showing signs of renewed interest.

See All

Company Information

  • Industry
  • Services